chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 21.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Pericarditis, Troponin I increased
Clinical narrative: This report was received from the investigator in the trial on 12 April 2010. A 21 year-old male subject received the following vaccines on 22 April 2009: ACAM2000 (lot number not reported); TYPHIM VI (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Nineteen days after vaccination, the subject was diagnosed with acute pericarditis, unspecified. The subject had no significant medical history. On 04 May 2009 (12 days after vaccination), the subject had an electrocardiogram, an echocardiogram and a Troponin I. All were reported as abnormal. The outcome was not reported. There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study.
Age: 21.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, TYP
Symptoms: Echocardiogram normal, Electrocardiogram normal, Pericarditis, Troponin I
Clinical narrative: This report was received from the investigator in the trial on 12 April 2010. A 21 year-old male subject received the following vaccines on 22 April 2009: ACAM2000 (lot number not reported); TYPHIM VI (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Nineteen days after vaccination, the subject was diagnosed with acute pericarditis, unspecified. The subject had no significant medical history. On 04 May 2009 (12 days after vaccination), the subject had an electrocardiogram, an echocardiogram and a Troponin I. All were reported as abnormal. The outcome was not reported. There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study.
Age: 19.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Pericardial disease, Troponin I increased
Clinical narrative: This report was received from the investigator in a trial on 13 April 2010. A 19 year-old male subject received the following vaccines on 11 January 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Eleven days after vaccination, the subject was diagnosed with unspecified disease of the pericardium. On 22 January 2009, the subject had a Troponin I and electrocardiogram which were reported as abnormal. On 03 February 2009, the subject had an echocardiogram which was also abnormal. The subject had no significant medical history. The outcome was not reported. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Pericardial disease, Troponin I
Clinical narrative: This report was received from the investigator in a trial on 13 April 2010. A 19 year-old male subject received the following vaccines on 11 January 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Eleven days after vaccination, the subject was diagnosed with unspecified disease of the pericardium. On 22 January 2009, the subject had a Troponin I and electrocardiogram which were reported as abnormal. On 03 February 2009, the subject had an echocardiogram which was also abnormal. The subject had no significant medical history. The outcome was not reported. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 22.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, ANTH, SMALL
Symptoms: Blood creatine phosphokinase decreased, C-reactive protein increased, Chest pain, Myocarditis, Myoglobin blood increased
Clinical narrative: This report was received from the investigator in a trial on 12 April 2010. A 22 year-old male subject received the following vaccines on 14 March 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Eleven days after vaccination, the subject was diagnosed with non-specific myocarditis. The subject was also diagnosed with unspecified disease of the pericardium 12 days after vaccination. The subject had a history of headaches. A Troponin I, drawn on Day 12, was 5.4 (abnormal). The outcome was not reported. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 22.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, ANTH, SMALL
Symptoms: Pericarditis, Troponin I increased
Clinical narrative: This report was received from the investigator in a trial on 12 April 2010. A 22 year-old male subject received the following vaccines on 14 March 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Eleven days after vaccination, the subject was diagnosed with non-specific myocarditis. The subject was also diagnosed with unspecified disease of the pericardium 12 days after vaccination. The subject had a history of headaches. A Troponin I, drawn on Day 12, was 5.4 (abnormal). The outcome was not reported. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 22.0
Sex: M
Vaccine: ANTH, SMALL, TYP, ANTH, SMALL, ANTH, SMALL
Symptoms: Myocarditis, Pericardial disease, Troponin I increased
Clinical narrative: This report was received from the investigator in a trial on 12 April 2010. A 22 year-old male subject received the following vaccines on 14 March 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Eleven days after vaccination, the subject was diagnosed with non-specific myocarditis. The subject was also diagnosed with unspecified disease of the pericardium 12 days after vaccination. The subject had a history of headaches. A Troponin I, drawn on Day 12, was 5.4 (abnormal). The outcome was not reported. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: FLUX, SMALL, TYP, YF
Symptoms: Asthenia, Bacteraemia, Cold agglutinins positive, Dysphagia, Echocardiogram normal
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 349416. An 18 year old male patient received the following vaccines on 13 December 1986: a subcutaneous injection of YF-VAX (lot number not reported); an intramuscular injection of influenza vaccine (manufacturer and lot number not reported); a percutaneous injection in the left upper arm of smallpox vaccine (other manufacturer, lot number not reported); and a subcutaneous injection of typhoid vaccine (manufacturer and lot number not reported). The site of administration was only reported for the smallpox vaccine. On the same day as vaccination, the patient began to feel exhausted and weak. He developed nausea and vomiting, inability to swallow, and fever (temperature not taken). The patient also developed rapid onset of swelling to the left upper arm (where the smallpox vaccine was given) along with rash which was initially noticed on chest. The rash spread to both arms with the majority on the chest. The rash reportedly "looked like mosquito bites". The patient's symptoms worsened and he was seen in the Emergency Room the following day. He was initially diagnosed with cellulitis at the site of immunization and was hospitalized to rule out sepsis. The patient remained in the hospital for the following 4 weeks. The patient tested positive for staph and had an increased cold agglutinins titer (doubled from 1:32 to 1:512). An echocardiogram showed no evidence of vegetation. He was treated successfully with IV antibiotics. The diagnosis at discharge was "bacteremia secondary to staph secondary to possible inoculation immunization". After review of medical records received on 23 June 2009 for dates of service 13 December 1986 to 4 February 2005, the event was assessed as sepsis with diffuse rash temporally associated with receipt of vaccines. No additional information is provided. List of documents held by sender: none.
Age: 18.0
Sex: M
Vaccine: FLUX, SMALL, TYP, YF
Symptoms: Fatigue, Immunisation reaction, Injection site cellulitis, Injection site swelling, Nausea
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 349416. An 18 year old male patient received the following vaccines on 13 December 1986: a subcutaneous injection of YF-VAX (lot number not reported); an intramuscular injection of influenza vaccine (manufacturer and lot number not reported); a percutaneous injection in the left upper arm of smallpox vaccine (other manufacturer, lot number not reported); and a subcutaneous injection of typhoid vaccine (manufacturer and lot number not reported). The site of administration was only reported for the smallpox vaccine. On the same day as vaccination, the patient began to feel exhausted and weak. He developed nausea and vomiting, inability to swallow, and fever (temperature not taken). The patient also developed rapid onset of swelling to the left upper arm (where the smallpox vaccine was given) along with rash which was initially noticed on chest. The rash spread to both arms with the majority on the chest. The rash reportedly "looked like mosquito bites". The patient's symptoms worsened and he was seen in the Emergency Room the following day. He was initially diagnosed with cellulitis at the site of immunization and was hospitalized to rule out sepsis. The patient remained in the hospital for the following 4 weeks. The patient tested positive for staph and had an increased cold agglutinins titer (doubled from 1:32 to 1:512). An echocardiogram showed no evidence of vegetation. He was treated successfully with IV antibiotics. The diagnosis at discharge was "bacteremia secondary to staph secondary to possible inoculation immunization". After review of medical records received on 23 June 2009 for dates of service 13 December 1986 to 4 February 2005, the event was assessed as sepsis with diffuse rash temporally associated with receipt of vaccines. No additional information is provided. List of documents held by sender: none.
Age: 18.0
Sex: M
Vaccine: FLUX, SMALL, TYP, YF
Symptoms: Pyrexia, Rash, Sepsis, Staphylococcal infection, Staphylococcus test positive
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 349416. An 18 year old male patient received the following vaccines on 13 December 1986: a subcutaneous injection of YF-VAX (lot number not reported); an intramuscular injection of influenza vaccine (manufacturer and lot number not reported); a percutaneous injection in the left upper arm of smallpox vaccine (other manufacturer, lot number not reported); and a subcutaneous injection of typhoid vaccine (manufacturer and lot number not reported). The site of administration was only reported for the smallpox vaccine. On the same day as vaccination, the patient began to feel exhausted and weak. He developed nausea and vomiting, inability to swallow, and fever (temperature not taken). The patient also developed rapid onset of swelling to the left upper arm (where the smallpox vaccine was given) along with rash which was initially noticed on chest. The rash spread to both arms with the majority on the chest. The rash reportedly "looked like mosquito bites". The patient's symptoms worsened and he was seen in the Emergency Room the following day. He was initially diagnosed with cellulitis at the site of immunization and was hospitalized to rule out sepsis. The patient remained in the hospital for the following 4 weeks. The patient tested positive for staph and had an increased cold agglutinins titer (doubled from 1:32 to 1:512). An echocardiogram showed no evidence of vegetation. He was treated successfully with IV antibiotics. The diagnosis at discharge was "bacteremia secondary to staph secondary to possible inoculation immunization". After review of medical records received on 23 June 2009 for dates of service 13 December 1986 to 4 February 2005, the event was assessed as sepsis with diffuse rash temporally associated with receipt of vaccines. No additional information is provided. List of documents held by sender: none.
Age: 18.0
Sex: M
Vaccine: FLUX, SMALL, TYP, YF
Symptoms: Vomiting
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 349416. An 18 year old male patient received the following vaccines on 13 December 1986: a subcutaneous injection of YF-VAX (lot number not reported); an intramuscular injection of influenza vaccine (manufacturer and lot number not reported); a percutaneous injection in the left upper arm of smallpox vaccine (other manufacturer, lot number not reported); and a subcutaneous injection of typhoid vaccine (manufacturer and lot number not reported). The site of administration was only reported for the smallpox vaccine. On the same day as vaccination, the patient began to feel exhausted and weak. He developed nausea and vomiting, inability to swallow, and fever (temperature not taken). The patient also developed rapid onset of swelling to the left upper arm (where the smallpox vaccine was given) along with rash which was initially noticed on chest. The rash spread to both arms with the majority on the chest. The rash reportedly "looked like mosquito bites". The patient's symptoms worsened and he was seen in the Emergency Room the following day. He was initially diagnosed with cellulitis at the site of immunization and was hospitalized to rule out sepsis. The patient remained in the hospital for the following 4 weeks. The patient tested positive for staph and had an increased cold agglutinins titer (doubled from 1:32 to 1:512). An echocardiogram showed no evidence of vegetation. He was treated successfully with IV antibiotics. The diagnosis at discharge was "bacteremia secondary to staph secondary to possible inoculation immunization". After review of medical records received on 23 June 2009 for dates of service 13 December 1986 to 4 February 2005, the event was assessed as sepsis with diffuse rash temporally associated with receipt of vaccines. No additional information is provided. List of documents held by sender: none.
Age: 37.0
Sex: F
Vaccine: TTOX
Symptoms: Dehydration, Fatigue, Injection site erythema, Injection site swelling, Lymphadenopathy
Clinical narrative: This case was received from a health professional on 31 July 2009. A 37-year-old female patient, with no reported medical history, received an intramuscular injection of Tetanus Toxoid Adsorbed Preservative-free (lot number U2883BA) on 18 July 2009. The patient was taking ADDERALL-XR and Levothyroxine concomitantly, and was participating in a tetanus hyper-immunization program to manufacturer tetanus immunoglobulin. Per the reporter, the patient had not received any previous tetanus immunization. One day after receiving the vaccine, on 19 July 2009, the patient developed redness and swelling at the injection site. She also experienced fatigue, fever up to 103 degrees Fahrenheit, dehydration, and swollen axillary lymph nodes. She was seen in the emergency department and treated with intravenous fluids, DECADRON, MOTRIN, and acetaminophen. She responded well to treatment, and was released home feeling well. Follow-up information was received from the health care professional on 11 September 2009. Tetanus Toxoid Adsorbed Preservative-free, 0.5 mL, was administered intramuscularly in the right deltoid. The patient was taking levothyroxine for hypothyroidism, and ADDERALL for ADD (attention deficit disorder). No testing was performed at the reporter's facility, and emergency room test results were unknown. In response to a question regarding recovery status, the reporter noted again that the patient "was released home feeling well". It was also noted that the patient was no longer eligible to participate in the tetanus toxoid hyper-immunization program. No additional information was reported.
Age: 37.0
Sex: F
Vaccine: TTOX
Symptoms: Pyrexia
Clinical narrative: This case was received from a health professional on 31 July 2009. A 37-year-old female patient, with no reported medical history, received an intramuscular injection of Tetanus Toxoid Adsorbed Preservative-free (lot number U2883BA) on 18 July 2009. The patient was taking ADDERALL-XR and Levothyroxine concomitantly, and was participating in a tetanus hyper-immunization program to manufacturer tetanus immunoglobulin. Per the reporter, the patient had not received any previous tetanus immunization. One day after receiving the vaccine, on 19 July 2009, the patient developed redness and swelling at the injection site. She also experienced fatigue, fever up to 103 degrees Fahrenheit, dehydration, and swollen axillary lymph nodes. She was seen in the emergency department and treated with intravenous fluids, DECADRON, MOTRIN, and acetaminophen. She responded well to treatment, and was released home feeling well. Follow-up information was received from the health care professional on 11 September 2009. Tetanus Toxoid Adsorbed Preservative-free, 0.5 mL, was administered intramuscularly in the right deltoid. The patient was taking levothyroxine for hypothyroidism, and ADDERALL for ADD (attention deficit disorder). No testing was performed at the reporter's facility, and emergency room test results were unknown. In response to a question regarding recovery status, the reporter noted again that the patient "was released home feeling well". It was also noted that the patient was no longer eligible to participate in the tetanus toxoid hyper-immunization program. No additional information was reported.
Age: 46.0
Sex: M
Vaccine: ANTH, HEP, SMALL, ANTH, HEP, SMALL
Symptoms: Echocardiogram normal, Electrocardiogram abnormal, Myocarditis, Nuclear magnetic resonance imaging normal, Troponin I
Clinical narrative: This report was received from the investigator on 20 May 2010. A 46 year-old male subject received the following vaccine on 25 August 2009: smallpox vaccine, (ACAM2000, lot number not reported); anthrax (manufacturer and lot number not reported) and hepatitis B ( manufacturer and lot number not reported). Fifteen days after vaccination, on 10 September 2009, the subject was diagnosed with and unspecified acute myocarditis. The subject had an abnormal electrocardiogram result on 10 September 2009 and a normal echocardiogram on 14 September 2009. The Troponin I result was not available. An MRI of the heart performed on 16 September 2009 was normal. No other information was provided. Additional information will be requested from the investigator. Note: There is no reported causality assessment.
Age: 31.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Echocardiogram normal, Electrocardiogram abnormal, Myocarditis, Troponin I increased
Clinical narrative: This study case was received from the investigator (MILVAX) on 06 May 2010. A 31 year-old male subject with a medical history significant for elevated cholesterol was vaccinated with ACAM2000 on 10 September 2009. Fourteen days post-vaccination, the subject had an abnormal troponin I result (18.22) on 23 September 2009 and an abnormal electrocardiogram (results not provided) on 24 September 2009. An echocardiogram performed on 24 September 2009 was normal. The subject was diagnosed with non-specific myocarditis (ICD-9 code 429.0) on 24 September 2009. No other information was provided. The outcome of the subject was not reported. List of documents held by sender: None. Additional information will be requested from the investigator. There is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study.
Age: 31.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Electrocardiogram abnormal, Myocarditis, Troponin I increased
Clinical narrative: This study case was received from the investigator (MILVAX) on 06 May 2010. A 31 year-old male subject with a medical history significant for elevated cholesterol was vaccinated with ACAM2000 on 10 September 2009. Fourteen days post-vaccination, the subject had an abnormal troponin I result (18.22) on 23 September 2009 and an abnormal electrocardiogram (results not provided) on 24 September 2009. An echocardiogram performed on 24 September 2009 was normal. The subject was diagnosed with non-specific myocarditis (ICD-9 code 429.0) on 24 September 2009. No other information was provided. The outcome of the subject was not reported. List of documents held by sender: None. Additional information will be requested from the investigator. There is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study.
Age: 36.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL
Symptoms: Echocardiogram normal, Electrocardiogram normal, Myocarditis, Troponin I increased
Clinical narrative: A 36-year-old male subject with no significant medical history received the following vaccines on 14 September 2009: smallpox vaccine, (ACAM2000, lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Twenty-four days after vaccination, the subject was diagnosed with non-specific myocarditis. On Day 9 (September 2009), the subject had normal electrocardiogram. On Day 11 (25 September 2009), the subject had a Troponin I of 0.25 (abnormal) and an echocardiogram which was normal. The outcome was not reported. Additional information will be requested from the investigator. Note: There is no reported causality assessment. List of documents held be sender: None
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL
Symptoms: Echocardiogram normal, Electrocardiogram abnormal, Myocarditis, Pericardial disease, Troponin I increased
Clinical narrative: This report was received from an investigator in a trial on 20 May 2010. A 20 year-old male subject with a history of eczema received the following vaccines on 24 September 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). The subject had previously received influenza vaccine, split virus (manufacturer unknown and lot number not reported) on 16 September 2009. Thirteen days after receipt of smallpox vaccine, the subject was diagnosed with unspecified disease of the pericardium. The subject was also diagnosed with non-specific myocarditis 14 days after vaccination. On Day 11 (05 October 2009), the subject had an abnormal electrocardiogram and a normal echocardiogram. On Day 13 (07 October 2009), the subject had a Troponin I of 12.3 (abnormal). The outcome was not reported. Additional information will be requested from the investigator. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 21.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL
Symptoms: Chest pain, Electrocardiogram abnormal, Myalgia, Pyrexia, Troponin increased
Clinical narrative: This case was received on 01 March 2010 via a QScan search on the VAERS database under reference number 367474. A 21 year old male patient received the following vaccines on 02 November 2009: a percutaneous injection of ACAM2000 (lot number W04-003) and an intramuscular injection of BIOTHRAX (Emergent Biosolutions, lot number FAV219). The sites of administration were not reported. Eleven days post-vaccination, the patient developed chest pain, low grade fever and myalgias. Troponin level and electrocardiogram were reported as abnormal. The outcome was not reported. No additional information was provided. List of documents held by sender: none.
Age: 21.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Myocarditis, Troponin I increased
Clinical narrative: This case was received on 01 March 2010 via a QScan search on the VAERS database under reference number 367474. A 21 year old male patient received the following vaccines on 02 November 2009: a percutaneous injection of ACAM2000 (lot number W04-003) and an intramuscular injection of BIOTHRAX (Emergent Biosolutions, lot number FAV219). The sites of administration were not reported. Eleven days post-vaccination, the patient developed chest pain, low grade fever and myalgias. Troponin level and electrocardiogram were reported as abnormal. The outcome was not reported. No additional information was provided. List of documents held by sender: none.
Age: 21.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL
Symptoms: Chest pain, Electrocardiogram abnormal, Myalgia, Pyrexia, Troponin increased
Clinical narrative: This report was received from the investigator in a trial on 20 May 2010. A 21 year-old male subject with no significant medial history received the following vaccines on 02 November 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Twelve days after vaccination, the subject was diagnosed with other an unspecified acute myocarditis. On Day 12 (14 November 2009), the subject had a Troponin I of 16.2 (abnormal) and an electrocardiogram and echocardiogram which were both abnormal. The outcome was not reported. Additional information will be requested from the investigator. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 21.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL
Symptoms: Echocardiogram abnormal, Electrocardiogram abnormal, Myocarditis, Troponin I increased
Clinical narrative: This report was received from the investigator in a trial on 20 May 2010. A 21 year-old male subject with no significant medial history received the following vaccines on 02 November 2009: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Twelve days after vaccination, the subject was diagnosed with other an unspecified acute myocarditis. On Day 12 (14 November 2009), the subject had a Troponin I of 16.2 (abnormal) and an electrocardiogram and echocardiogram which were both abnormal. The outcome was not reported. Additional information will be requested from the investigator. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Age: 19.0
Sex: F
Vaccine: ANTH, FLUN3, SMALL, TYP
Symptoms: Dizziness, Hypoaesthesia, Paraesthesia
Clinical narrative: This case was received on 01 March 2010 via a QScan search on the VAERS database, under reference number 368489. A 19 year old female patient received the following vaccines on 12 November 2009: a percutaneous injection of ACAM2000 (lot number VV04003A); an intramuscular injection of TYPHIM VI (lot number 00191-2); an intramuscular injection of anthrax vaccine (manufacturer unknown, lot number FAV279); and an intranasal dose of FLUMIST (Medimmune, lot number 5W737P). After vaccination, the patient felt faint, experienced tingling in the legs and numbness. The patient's blood pressure was 110/60 and pulse was 40. The patients was monitored for 20 minutes and released. The patient recovered. Note: Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination and the lot number has been verified as an ACAM2000 lot number. List of documents held by sender: none.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: Bacterial test negative, Blood glucose, Blood immunoglobulin G normal, Brucella test negative, CSF culture negative
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: CSF glucose, CSF immunoglobulin G index, CSF immunoglobulin increased, CSF myelin basic protein increased, CSF pressure normal
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: CSF protein increased, CSF virus no organisms observed, CSF white blood cell count increased, Cerebellar syndrome, Cryptococcus test
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: Cytomegalovirus test negative, Enterovirus test negative, Epstein-Barr virus test negative, HIV test negative, Headache
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: Herpes simplex serology negative, Human herpes virus 6 serology negative, Hyperreflexia, Lymphocyte percentage increased, Monocyte percentage increased
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: Muscular weakness, Mycobacterium test negative, Mycoplasma test, Nausea, Neutrophil percentage decreased
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.
Age: 23.0
Sex: M
Vaccine: YF
Symptoms: Nuchal rigidity, Nuclear magnetic resonance imaging brain abnormal, Nystagmus, Paraesthesia, Paraparesis
Clinical narrative: Literature report received on 26 October 2009. Case report: "A 23-year-old previously healthy man received immunization against yellow fever (17-D-204) 2 weeks prior to a travel out of country. Three weeks later, he developed fever, nausea, vomiting, severe bifrontal headaches and photophobia, followed by ascending weakness of the lower limbs, paresthesias of his feet, and urinary retention. On examination, he was febrile, had mild nuchal rigidity, and exhibited unsustained horizontal nystagmus on left gaze, discrete left arm dysemtria, bilateral symmetric lower extremity paresis, patellar and ankle hyperreflexia, and impaired sensation to light-touch and pinpick with an ill defined sensory level around T9. Magnetic resonance imaging (MRI) of the brain and spinal cord showed areas of high signal intensity on T2 weighted and fluid attenuation inversion recovery (FLAIR) in the middle cerebellar penduncle, right dorsal medulla oblongata and a multilevel lesion involving the thoracic spinal cord with subtle patchy heterogeneous enhancement after administration of gadolinium. Cerebrospinal fluid (CSF) analysis showed clear and colorless fluid with a normal opening pressure. Cell count was elevated with 62 white blood cells (neutrophils 41%, lymphocytes 46%, monocytes 13%) 17 red blood cells, glucose 54 mg/100mL (serum glucose 154 mg/100mL) and a protein content of 105 mg/dL. CSF cultures were negative. Serum and CSF evaluations for herpes simplex virus type 1 and 2, epstein barr virus, human T-lymphotropic virus 1 and 2, rabies virus, arbovirus, barthonella quintana, rickettsias, brucellas spp, leptospiras, salmonella, borrelias, mycobaterias, treponema pallidum, plasmodium, cryptococcus and mycoplasma were negative. CSF myelin basic protein (MBP) was elevated with a level of 618 ng/mL. CSF total IgG level, and IgG index were normal. CSF specific IgM antibodies to YEL levels were elevated with a level of 15.6, IgM and IgG specific antibodies to YEL levels in serum were 4.8 and 1.4 respectively (normal is less than 2.0). The patient received a five-day course of 1 gram daily of intravenous methylprednisolone, with marked clinical improvement. MRI of brain and entire spine showed resolution of previous lesions 30 days after initiation of therapy." Follow-up information received 09 November 2009 from a co-author of the literature report. The reporter confirmed that the patient had been vaccinated in the country, not out of the country. The vaccine administered was YF VAX (lot number not reported). No additional information was provided.